Myovant Sciences Ltd. (MYOV), relating to its proposed acquisition by Sumitovant Bopharma Ltd. and Sumitomo Pharma Co., Ltd. Under the terms of the agreement, MYOV shareholders are expected to receive $27.00 in cash per share they own.
Myovant Sciences Ltd. (MYOV), relating to its proposed acquisition by Sumitovant Bopharma Ltd. and Sumitomo Pharma Co., Ltd. Under the terms of the agreement, MYOV shareholders are expected to receive $27.00 in cash per share they own.